Melanomas bearing class II mutations are less sensitive to BRAF inhibitors than those with class I mutations; however, class II-mutant melanomas are sensitive to double inhibition with BRAF and MEK inhibitors [18]. This evidence concerns the gene MAP2K7 and melanoma.